

Chlamydomphila Pneumonia

Mona Z Zaghloul*

Department of Clinical Pathology, Ain Shams University Hospitals, Cairo, Egypt

*Corresponding author: Mona Z Zaghloul, Microbiology Unit, Department of Clinical Pathology, Ain Shams University Hospitals, Cairo, Egypt, Tel: 02-24023494; E-mail: monazaki_810@hotmail.com

Received date: May 20, 2015, Accepted date: May 22, 2015, Published date: May 26, 2015

Copyright: © 2015 Zaghloul MZ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Chlamydomphila pneumoniae (formerly *Chlamydia pneumoniae* (is a Gram-negative intracellular bacterium [1] responsible for acute upper and lower respiratory tract infections. The first known case of infection with *C. pneumoniae* was a case of sinusitis in Taiwan. This atypical bacterium commonly causes pharyngitis, bronchitis, sinusitis [2] and atypical pneumonia [3] not only in elderly and debilitated patients, but also in healthy adults [4]. The term atypical pneumonia was used by Reiman in 1938 to describe the infection of non-characteristic course resistant to sulphonamide therapy [5]. Some researchers used the term "infections with atypical pathogens" to describe infection caused by *Chlamydia*, *Mycoplasma* and *Legionella* [6]. In addition to pneumonia, *C. pneumoniae* causes extrapulmonary manifestations include nervous system disorders such as Guillain-Baré syndrome and meningoencephalitis as well as atherosclerosis and coronary artery disease [7], reactive arthritis [8] and myocarditis [9].

Specific diagnosis of infection with atypical pathogens is important because treatment with routinely used β -lactam antibiotics is ineffective against these organisms, and atypical pneumonia can sometimes develop a severe clinical course. The isolation of *C. pneumoniae* in cell cultures as HEP-2 and HL cells require multiple passages over a period of weeks to show a positive result [10]. Failure to isolate the pathogen may be due to inadequate sample, specimen toxicity in cell culture or loss of specimen viability during transportation. Antigen detection tests include direct fluorescent antibody assays (DFA) and enzyme immunoassays (EIA) have the advantage of rapid turnaround time. Diagnosis of acute *C. pneumoniae* infection is based on paired serum samples obtained 4 to 8 weeks apart showing a 4-fold increase in IgG antibody titer, or on a single sample showing IgM antibody positivity [11]. IgA antibodies may be a marker of persistent infection and has been used in the definition of chronic *C. pneumoniae* infection [12]. The microimmunofluorescence (MIF) assay developed by Wang et al., [13] is considered the gold standard for *Chlamydia* serology today. It was proved to be suitable for routine diagnosis [14]. In the MIF test, purified elementary bodies are used to detect *Chlamydia*-specific antibodies in the IgM, IgG, and IgA serum fractions. The diagnostic criteria were a significant increase in specific antibody titer in paired serum samples, a very high specific IgG antibody titer, or the presence of IgM antibodies against *C. pneumoniae* [15]. Polymerase chain reaction (PCR) techniques have been developed for the detection of *C. pneumoniae* DNA [16]. Johansson et al, [17] reported that PCR was more sensitive than conventional microbiological methods and it could help to increase the microbial yield for patients with community acquired pneumonia.

References

1. Cosentini R, Blasi F (1996) New pathogens for respiratory infections. *Curr Opin Pulm Med* 2: 174-180.
2. Grayston JT, Kuo CC, Wang SP, Altman J (1986) A new *Chlamydia psittaci* strain, TWAR, isolated in acute respiratory tract infections. *N Engl J Med* 315: 161-168.
3. Lang BR (1991) *Chlamydia pneumoniae* as a differential diagnosis? Follow-up to a case report on progressive pneumonitis in an adolescent Patient *Care* 15: 1
4. Little, Linda (1991) Elusive pneumonia strain frustrates many clinicians, *Medical Tribune*, September 19: 6.
5. Puzio J, Kucewicz E, SioÅ,a M, Dworniczak A, Wojarski J, et al. (2009) [Atypical and opportunistic pulmonary infections after cardiac surgery]. *Anestezjol Intens Ter* 41: 41-45.
6. Fields BS, Benson RF, Besser RE (2002) *Legionella* and Legionnaires' disease: 25 years of investigation. *Clin Microbiol Rev* 15: 506-526.
7. Deniset JF, Pierce GN (2010) Possibilities for therapeutic interventions in disrupting *Chlamydomphila pneumoniae* involvement in atherosclerosis. *Fundam Clin Pharmacol* 24: 607-617.
8. Cascina A, Marone Bianco A, Mangiarotti P, Montecucco CM, Meloni F (2002) Cutaneous vasculitis and reactive arthritis following respiratory infection due to *Chlamydia pneumoniae*: report of a case. *Clin Exp Rheumatol* 20: 845-847.
9. Gran JT, Hjetland R, Andreassen AH (1993) Pneumonia, myocarditis and reactive arthritis due to *Chlamydia pneumoniae*. *Scand J Rheumatol* 22: 43-44.
10. Augenbraun MH, Roblin PM, Chirgwin K, Landman D, Hammerschlag MR (1991) Isolation of *Chlamydia pneumoniae* from the lungs of patients infected with the human immunodeficiency virus. *J Clin Microbiol* 29: 401-402.
11. Peeling RW (1995) Laboratory diagnosis of *Chlamydia pneumoniae* infections. *Can J Infect Dis* 6: 198-203.
12. von Hertzen L, Isoaho R, Leinonen M, Koskinen R, Laippala P, et al. (1996) *Chlamydia pneumoniae* antibodies in chronic obstructive pulmonary disease. *Int J Epidemiol* 25: 658-664.
13. Wang SP, Grayston JT, Kuo CC, Alexander ER, Holmes KK (1977) Serodiagnosis of *Chlamydia trachomatis* infection with the microimmunofluorescence test. In: Hobson D, Holmes KK, editors. *Nongonococcal Urethritis and Related Infections*. Washington: American Society for Microbiology 237-48.
14. Wang SP, Grayston JT, Alexander ER, Holmes KK (1975) Simplified microimmunofluorescence test with trachoma-lymphogranuloma venereum (*Chlamydia trachomatis*) antigens for use as a screening test for antibody. *J Clin Microbiol* 1: 250-255.
15. Verkooyen RP, Hazenberg MA, Van Haaren GH, Van Den Bosch JM, Snijder RJ, et al. (1992) Age-related interference with *Chlamydia pneumoniae* microimmunofluorescence serology due to circulating rheumatoid factor. *J Clin Microbiol* 30: 1287-90.
16. Black CM, Fields P, Messmer TO, Berdal BP (1994) Detection of *Chlamydia pneumoniae* in clinical specimens by polymerase chain reaction using nested primers. *Eur J Clin Microbiol Infect Dis* 13: 752-756.

17. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J (2010) Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. *Clinical Infectious Diseases* 50: 202-209.